Emmis Acquisition (EMIS) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Emmis Acquisition (EMIS) has outperformed Entrada Therapeutics (TRDA) over the past year, gaining 3.3% versus a loss of 25.6%. Entrada Therapeutics is the larger company by market cap ($170.2 million vs $162.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EMIS | TRDA |
|---|---|---|
| Share price | $10.28 | $4.37 |
| Market cap | $162.18M | $170.15M |
| 1-day change | +0.10% | -8.58% |
| YTD return | +3.32% | -57.49% |
| 1-year return | +3.32% | -25.55% |
| EPS (TTM) | — | $-3.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $25.42M |
| Revenue growth (YoY) | — | -87.94% |
| Net income (latest FY) | — | $-143.75M |
| Operating margin | — | -621.13% |
| Net margin | — | -565.48% |
| 52-week high | $10.28 | $16.45 |
| 52-week low | $9.90 | $4.11 |
| Distance from 52-week high | 0.00% | -73.43% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +334.78% |
| Average volume | 14.46K | 355.10K |
| Shares outstanding | 11.94M | 38.94M |
| Employees | — | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EMIS has outperformed TRDA by 28.9 percentage points over the past year.
About Emmis Acquisition
EMIS stock →Emmis Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Health Care · Biotechnology: Pharmaceutical Preparations
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
EMIS vs TRDA FAQ
Which is bigger, Emmis Acquisition or Entrada Therapeutics?
Entrada Therapeutics (TRDA) is larger, with a market capitalization of $170.15M compared with $162.18M for Emmis Acquisition (EMIS).
Which stock has performed better over the past year, EMIS or TRDA?
EMIS returned +3.32% over the past 12 months, compared with -25.55% for TRDA (price return, excluding dividends). Past performance does not predict future results.
Are Emmis Acquisition and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.